Malaria-resisting arteannuin naphthoquine compound composition

A composition and malaria technology, applied in the direction of drug combination, active ingredients of heterocyclic compounds, and resistance to vector-borne diseases, etc., can solve the problems of raw material cost and less toxic and side effects, and achieve the effect of easy acceptance and promotion, and guaranteed effect

Active Publication Date: 2008-02-06
李国桥 +1
View PDF3 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Although the above-mentioned products can meet the general purpose of treating malaria, there is still a need for better raw materials, simpler processes, lower cost of ra

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Accurately weigh 160 g of artemisinin, 400 g of naphthoquine, and 4 g of primaquine, and mix them, then add 28 g of hydroxypropyl cellulose and 34 g of compressible starch, and mix uniformly. Mix the above raw and auxiliary materials evenly, add 3% hydroxypropyl methylcellulose pulp to make a soft material, pass through a 12-mesh sieve to granulate, and dry at 60°C ± 2°C to control the water content of the granules to be 2.5%-3.5% . The dry granules are sized with a 16-mesh sieve, then add 5% sodium carboxymethyl starch and 1.0% magnesium stearate by weight of the dry granules, mix well, accurately weigh an appropriate amount, measure the drug content, and calculate the set tablet weight. , select special-shaped die pressing, and make 1000 pieces. The Opadry film coating material was added into 80% ethanol, stirred and dispersed evenly, and passed through a 100-mesh sieve for use. Put the tablets into the coating pan, preheat to 40-50°C, adjust the air pressure of the...

experiment example

[0026] The inventors conducted clinical research by comparing the composition of the present invention with the control group.

[0027] A total of 315 cases of uncomplicated falciparum malaria were treated in the highly endemic area of ​​multidrug-resistant falciparum malaria on the Cambodia-Thailand border in western Cambodia, of which 103 cases were in the artemisinin naphthoquin tablet (artemisinin 160mg + naphthoquin 400mg + primaquine 4mg) group , give the patient 2 tablets orally at a time. In the control group, 212 cases of compound naphloquine phosphate tablets (dihydroartemisinin 100mg + naphthoquine phosphate 600mg + trimethoprim 200mg) were orally administered to the patients for two days, one tablet per day. Follow up and review the resurgence of the protozoa once a week. The main curative effect evaluation indexes are the cure rate, the protozoa resurgence rate, the average protozoan overcast time, and the average fever reduction time. The results showed that th...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a medicine combination used to cure or prevent malaria, which basically consists of arteannuin or derivatives thereof, naphthoquine and primaquine. The invention can be used in curing malignant malaria, quartan malaria and tertian malaria and is particularly suitable to cure malignant malaria with multi-drug resistance through adopting one dose therapeutics. The invention has good curative effect, less toxic and side effect and low cost, thereby being particularly suitable for fast control and elimination of malaria in various regions.

Description

technical field [0001] The present invention relates to compound anti-malarial pharmaceutical compositions, more particularly to artemisinin-naphloquine compound anti-malarial pharmaceutical compositions, and their preparation methods and uses for preparing medicines for preventing, treating and controlling malaria. Background technique [0002] Malaria has always been a serious infectious disease that endangers human life and health. Malaria is prevalent in many countries and regions including Africa, Southeast Asia and China. Some unilateral antimalarial drugs are known in the prior art, and none of them can achieve a durable high cure rate and prevent drug resistance, nor can they quickly block transmission and control the prevalence of malaria. [0003] Chinese Patent Application No. 97111840.X discloses a method for preparing an antimalarial compound compound naphthoquine phosphate, which comprises mixing naphthoquine phosphate and artemisinin antimalarial compounds in ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/55A61K31/675A61K47/34A61K9/20A61K9/48A61K9/08A61K9/02A61K9/10A61P33/06A61K47/38
CPCY02A50/30
Inventor 李国桥宋健平
Owner 李国桥
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap